要旨：

• Regulatory agencies recommend quantitative justifications for clinical dose selection.
• T-cell engagers (TCE) pose particular challenges for dosing due to their multi-specific binding and avidity-based mechanism.
• We present an improved mathematical model where the target doses are sensitive to the cell-surface density of TCE targets, rather than receptor concentration.
• This model is robust to common discrepancies between experimental and clinical conditions, which often reduce accuracy of traditional models.

講演者：: Marc Presler, PhD, Associate Director, QSP